Back to search results

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Lymphoma · Lymphoma, Large B-Cell, Diffuse

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Miami Sylvester Cancer Center, Miami, Florida, United States

    Contact: Study coordinator (Juan Alderuccio, MD)

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Clare Phinney) · clare_phinney@dfci.harvard.edu
    Contact: Principal Investigator (Gottfried von Keudell, MD, PhD)

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Jennifer Crombie, MD)
    Contact: Study coordinator (Clare Phinney) · clare_phinney@dfci.harvard.edu
    Contact: Principal Investigator (Jennifer Crombie, MD)
Study leads

  • Jennifer Crombie, MD

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)